Press

Shasqi to Present Data on Novel Click Chemistry Platform at the American Association for Cancer Research (AACR) Annual Meeting

April 10, 2021

Shasqi to Present Data on Novel Click Chemistry Platform at the American Association for Cancer Research (AACR) Annual Meeting

- SQ3370 maximizes therapeutic benefit and reduces systemic cytotoxic exposure in preclinical models when compared to standard doxorubicin

- A Phase 1 clinical study of SQ3370 in advanced sarcomas and other solid tumors is ongoing

SAN FRANCISCO, April 10, 2021, Shasqi, a clinical stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) platform, will present preclinical data and the Phase 1 clinical trial design for its lead clinical candidate, SQ3370, at the upcoming virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

“Our preclinical studies of SQ3370, including IND-enabling toxicology models, continue to strongly support the potential of our CAPAC platform to result in therapies that can maximize the dose at a tumor while reducing systemic toxicities associated with powerful medicines such as doxorubicin,” said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi. “We believe this is a compelling approach that can help patients by dramatically improving the therapeutic window of existing medicines that are widely used but carry challenging toxicity profiles.”

Both preclinical and trial-in-progress posters will be available beginning the first day of the virtual meeting on Saturday, April 10, 2021, at 8:30 a.m. ET and remain available through June 21, 2021.

Preclinical Poster Presentation:
The CAPAC Platform maximizes therapeutic benefit and reduces systemic cytotoxic exposure in small and large animals
Abstract number: 1347
Session: PO.ET06.04. Novel Targets and Pathways
Key findings:

  • The maximum tolerated dose (MTD) of SQ3370 was nearly 20 times that of conventional doxorubicin in mice and 11 times that of conventional doxorubicin in rats.
  • In canine models, the highest non-severely toxic dose of SQ3370 was 8.95 times higher (8.95 mg/kg/cycle) when compared to the conventional dose of doxorubicin (1 mg/kg/cycle). At this dose, there were minimal systemic adverse events, all of which were reversible, and there was no evidence of cardiotoxicity. Together, these data highlight SQ3370’s enhanced safety.
  • The SQL70 biopolymer can be injected at multiple sites, and nearly 50% remains in situ for 2-4 weeks.
  • SQ3370 treatment demonstrated a dose-dependent effect on anti-tumor efficacy.

Trial-In-Progress Poster Presentation:
First-in-human Phase I study of SQ3370, a click activated protodrug therapy, in patients with advanced solid tumors
Abstract number: 5465
Session: PO.CT08.01. Phase I Clinical Trials in Progress
SQ3370 is the first click chemistry-based treatment to be tested in humans. A Phase 1 clinical study, SQ3370-001, is currently enrolling patients with advanced sarcomas and other solid tumors in the United States and Australia (ClinicalTrials.gov NCT04106492). The company presented preclinical and trial-in-progress data from the SQ3370 program in late 2020 and expects to report initial data from the study in 2021.

CAPAC and SQ3370:
SQ3370 utilizes Shasqi’s proprietary CAPAC platform, a click chemistry-based approach that activates cancer drugs at a tumor with decreased systemic toxicity. The platform utilizes the biocompatible chemical reaction between an attenuated trans-cyclooctene-modified protodrug and a tetrazine-modified biopolymer. The biopolymer is injected into the target tumor lesion, where it precisely captures and activates an infused protodrug. Unlike traditional targeted therapies, the CAPAC platform is agnostic to tumor characteristics that can vary from patient to patient, such as biomarker expression and enzymatic activity.

About Shasqi:
Shasqi is a privately held, clinical stage biotechnology company whose mission is to enable patients to beat cancer without poisoning their bodies. Shasqi leverages its proprietary CAPAC Platform to develop precision oncology therapeutics designed to improve efficacy while decreasing systemic toxicity. Shasqi’s CAPAC Platform is highly modular and can be applied to a broad range of drugs that are otherwise limited by toxicity, enabling the exploration of therapeutic biology in ways that were not previously possible.